Company Overview
CNS Pharmaceuticals, Inc. operates as a clinical pharmaceutical entity dedicated to the development of anti-cancer drug candidates specifically designed for the treatment of brain and central nervous system tumors. The company's portfolio includes specific candidates such as TPI 287 and Berubicin, which are currently advancing through Phase 2 clinical trials for the treatment of glioblastoma. This biotechnology company functions within the broader healthcare sector and the specialized biotechnology industry, positioning itself to address high-need oncology markets. In terms of scale, the company holds a market capitalization of $1.40M and employs a workforce of 4 individuals, while its annual revenue is listed as N/A. These valuation and revenue figures indicate that the company is an early-stage micro-cap biotechnology firm with minimal current commercial operations, reflecting a business model that prioritizes research and development expenditures over immediate revenue generation.
Financial Health
The company reports revenue of N/A for the trailing twelve months, alongside a net income of $-13,071,128 and an EBITDA of $-13,196,598. The significant negative net income relative to the reported revenue of N/A reveals a cost structure dominated by substantial research and development expenses and operational costs that exceed any current sales income. The free cash flow stands at $-11,833,992, which indicates that the company is burning cash rapidly, a common characteristic for clinical-stage biotechs that lack commercial product revenue streams. All three margin metrics—gross margin, operating margin, and profit margin—are reported at 0.0%, indicating that the company has not yet achieved profitability or generated revenue sufficient to calculate meaningful margins at this stage. Despite the negative earnings, the company maintains a cash balance of $9.86M against a total debt level of $30,793, resulting in a debt-to-equity ratio of 0.31. This balance sheet composition suggests a conservative leverage profile where liabilities are minimal relative to equity, though the cash reserve must be sufficient to fund ongoing clinical trials. The current ratio is 5.82, which indicates a strong short-term liquidity position with current assets significantly exceeding current liabilities. Furthermore, the Return on Equity is -197.1% and the Return on Assets is -85.6%, revealing that management effectiveness in generating returns is currently negative due to the heavy investment phase of the business model.
Valuation Assessment
The trailing twelve-month P/E ratio is 0.00, while the forward P/E is -6.26, a difference that implies expected earnings are projected to remain negative in the near term before potentially turning positive. The price-to-book ratio is 0.14, which indicates that the market values the company at a fraction of its net asset book value, reflecting the speculative nature of its asset-heavy development pipeline. The price-to-sales ratio is N/A because the company has no reported revenue, and the EV/EBITDA stands at 0.63, suggesting a valuation based on enterprise value relative to negative earnings is not a standard metric for this stage of development. The stock's 52-week high is $45.84 and the 52-week low is $2.06, meaning the current price sits at the lower end of its trading range relative to this volatility span. The beta value is 0.46, which means the stock's price volatility is significantly lower than the broader market, often due to low liquidity and a limited float of shares.
Growth & Income
The revenue growth year-over-year is N/A, and the earnings growth year-over-year is also N/A, meaning there are no historical growth rates available to compare earnings growth speed against revenue growth. Since the company does not pay dividends, there is no dividend yield or payout ratio to evaluate for sustainability. Consequently, the company operates as a non-dividend payer that reinvests its remaining cash reserves entirely into growth activities such as clinical trials and drug candidate development rather than distributing income to shareholders. This profile characterizes CNSP as a pure-play growth opportunity for investors seeking exposure to early-stage oncology assets rather than those looking for current income generation or established revenue growth metrics.